BrokerBank Securities Issues its Second Report on PuraMed BioScience Entitled “A Look at the Science Behind This Company’s Quest.”

SCHOFIELD, Wis.--(BUSINESS WIRE)--PuraMed BioScience, Inc. (OTCBB:PMBS) a pharmaceutical company engaged in the development and marketing of a line of revolutionary, new, non-prescription medicines targeting major consumer health needs including the treatment of headaches, insomnia and general pain announced today that BrokerBank Securities, Philip Wright, CFA, has published a second report in its investment coverage of PuraMed BioScience, Inc. entitled “A Look at the Science Behind This Company’s Quest.”